Roche's cobas pro clears FDA

By staff writers

September 16, 2019 -- Roche Diagnostics said the U.S. Food and Drug Administration (FDA) has cleared its cobas pro integrated solutions for high-volume clinical chemistry and immunochemistry testing in labs.

The system was designed to provide improved turnaround time for tests. According to the company, up to 2,200 tests can be done per hour, and cobas pro saves up to 3.25 hours in operating time per daily workload, compared with the older cobas 6000 series.

Roche announced in January that it had launched cobas pro integrated solutions in countries accepting the European CE Mark.

AACC preview: A rough guide to diagnostics on show
Bruce Carlson, longtime diagnostic market analyst and publisher of Kalorama Information, takes you on a trip through this year's product offerings at...
And the survey says: Labs rank experience with IVD vendors
Laboratorians in the U.S. and Europe ranked GenMark Diagnostics, BioMérieux, and Cepheid among the highest for overall customer experience in a recent...

Copyright © 2019

Last Updated np 10/29/2019 4:04:23 PM

Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.